Brain Navi Biotechnology

Brain Navi Biotechnology is a Taiwanese medical robotics company founded in 2015 by surgeon and entrepreneur Dr. Jerry Chen. The company is headquartered in Hsinchu Biomedical Science Park, a hub for technological talent in Taiwan. Dr. Chen's background as a urology director and biomedical engineering researcher provided him with insights into the needs of surgical robotics. Brain Navi focuses on developing high-precision robotic systems to assist surgeons, improve accuracy, and streamline surgical procedures.

The company's flagship product is the NaoTrac, an autonomous neurosurgical navigation robot. It utilizes a proprietary, patented SMART (Surface Mapping Auto-registration Technology) platform which combines machine vision, artificial intelligence, and robotics to enable real-time imaging and minimally invasive surgery. A key feature is its non-contact, frameless registration, which uses machine vision to map over 100,000 facial landmark check-points to align the patient's anatomy with preoperative CT and MRI scans, reducing setup time. The robotic arm then assists surgeons by precisely positioning instruments along a pre-planned trajectory, though the surgeon remains in control. This system is designed to be free from the need for a C-arm or O-arm, increasing its accessibility. The NaoTrac robot is applicable for a range of cranial procedures, including biopsies, tumor ablations, deep brain stimulation (DBS), and external ventricular drain (EVD) placement.

Brain Navi has achieved significant regulatory milestones, receiving a CE Mark in Europe (2021), approval from the Taiwan Food and Drug Administration (TFDA), and 510(k) clearance from the U.S. Food and Drug Administration (FDA) in June 2025. The company has expanded its global presence through partnerships, including with BenQ Medical Technology for the Chinese market and Palex Healthcare in Spain, where the first NaoTrac surgeries were performed in 2025. The company's business model involves selling these high-end medical devices to hospitals and medical centers worldwide. Brain Navi has received funding from institutional investors, including Sunsino Venture Group and Kyber Capital, and began IPO counseling in April 2025 to access public capital markets for further growth.

Keywords: neurosurgical navigation, robotic-assisted surgery, medical robotics, stereotactic surgery, minimally invasive surgery, machine vision, surgical guidance, NaoTrac, SMART platform, frameless registration, deep brain stimulation, brain biopsy, medical device, surgical automation, AI in surgery, medtech, EVD placement, neuro-endoscopy, KrystoLens, surgical planning